Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 276Carcinoma, Non-Small-Cell Lung 243Neoplasms 227Prostatic Neoplasms 185Colorectal Neoplasms 175Multiple Myeloma 135Lung Neoplasms 132Ovarian Neoplasms 118Neoplasm Metastasis 118Leukemia, Myeloid, Acute 107Pancreatic Neoplasms 102Melanoma 90Squamous Cell Carcinoma of Head and Neck 87Recurrence 78Endometrial Neoplasms 75Carcinoma, Renal Cell 71Lymphoma, Non-Hodgkin 70Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Lymphoma 66Stomach Neoplasms 64Glioblastoma 63Carcinoma, Hepatocellular 63Brain Neoplasms 62Glioma 60Sarcoma 57Head and Neck Neoplasms 57Uterine Cervical Neoplasms 56Triple Negative Breast Neoplasms 55Leukemia, Lymphocytic, Chronic, B-Cell 54Urinary Bladder Neoplasms 50

Interventions

Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Gastroenteropancreatic Neuroendocrine Tumor × 30 days × Clear all
NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
220 enrolled
EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡